2022 / 02

Next Paper
DOI: 10.24075/brsmu.2022.015

ORIGINAL RESEARCH

Experience of tocilizumab in hospital patients with moderate COVID-19

Burgasova OA1,2, Dolinniy SV3, Tetova VB1, Ogarkova DA2, Odnoralov MA1, Bakalin VV1, Smetanina SV3, Antipyat NA3, Taranova MV4
About authors

1 Peoples’ Friendship University of Russia, Moscow, Russia

2 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia

3 Clinical Hospital for Infectious Diseases №1, Moscow, Russia

4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Correspondence should be addressed: Olga A. Burgasova
Volokolamskoe sh., 47, str. 8, korp. 5, Moscow, 125310, Russia; ur.liam@avosagrubaglo

About paper

Author contribution: OA Burgasova — initiative and design, supervision of the clinical part of the study, writing of the manuscript; SV Dolinniy — literature review, clinical observations, data processing; VB Tetova — literature review, editing of the manuscript; DA Ogarkova — statistical analysis; MA Odnoralov, VV Baсalin — clinical observations, processing of clinical and laboratory data; SV Smetanina — concept; NA Antipyat — supervision of the clinical part of the study, MV Taranova — literature review, data processing.

Compliance with ethical standards: the study was approved by the ethics committee at the Clinical Hospital for Infectious Diseases №1 (Protocol 1 of January 11, 2021); all participants provided informed consent for the study.

Received: 2022-03-10 Accepted: 2022-04-03 Published online: 2022-04-15
|
  1. WHO Coronavirus (COVID-19) Dashboard (2021). Available from: https://covid19.who.int/ (Accessed 19 October, 2021).
  2. Song P, Li W, Xie J, et al. Cytokine storm induced by SARSCoV-2. Clin Chim Acta. 2020; 509: 280–7. DOI: 10.1016/j. cca.2020.06.017.
  3. Zhao Z, Wei Y, Tao C. An enlightening role for cytokine storm in coronavirus infection. Clin Immunol. 2021; 222: DOI: 10.1016/j. clim.2020.108615.
  4. Moradian N, Gouravani M, Salehi MA, et al. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality. Eur Cytokine Netw. 2020; 31 (3): 81–93. DOI: 10.1684/ecn.2020.0451.
  5. Pum A, Ennemoser M, Adage T, Kungl AJ. Cytokines and Chemokines in SARS-CoV-2 Infections—Therapeutic Strategies Targeting Cytokine Storm. Biomolecules. 2021; 11 (1): DOI: 10.3390/biom11010091.
  6. Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020; 131: DOI: 10.1016/j.biopha.2020.110698.
  7. Zhou Z, Price C. Overview on the use of IL6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opin Investig Drugs. 2020; 29 (12): 1407–12. DOI: 10.1080/13543784.2020.1840549.
  8. Chen J, Zhang L, Hou H, et al. Interleukin 6 signaling blockade treatment for cytokine release syndrome in COVID 19 (Review). Exp Ther Med. 2021; 21 (1): 24. DOI: 10.3892/etm.2020.9456.
  9. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020; 368 (6490): 473–4. DOI: 1126/ science. Abb 8925.
  10. Kumar A, Sharma A, Tirpude NV, Sharma S, Padwad YS, Kumar S. Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection. Inflammopharmacology. 2022 Jan 20: 1–27. DOI: 10.1007/ s10787-021-00903-x. Online ahead of print. PMID: 35048262.
  11. Jiang Y, Rubin L, Peng T, Liu L, Xing X, Lazarovici P, Zheng W. Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. Int J Biol Sci. 2022 Jan 1; 18 (2): 459–72. DOI: 10.7150/ijbs.59272. eCollection 2022. PMID: 35002503.
  12. Group A-TL-CS. A Neutralizing Monoclonal Antibody for Hospitalized Patients With Covid-19. N Engl J Med. 2020; 384 (10): 905–14. DOI: 10.1056/NEJMoa2033130.
  13. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients With Covid-19. N Engl J Med. 2020; 384 (3): 238–51. DOI: 10.1056/NEJMoa2035002.
  14. Verderese JP, Stepanova M, Lam B, Racila A, Kolacevski A, Allen D, et al. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience. Clin Infect Dis. 2021; DOI: 10.1093/cid/ciab579.
  15. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients With Covid-19. N Engl J Med. 2021; 384 (3): 229–37. DOI: 10.1056/NEJMoa2029849.
  16. Kulanthaivel S, Kaliberdenko VB, Balasundaram K, Shterenshis MV, Scarpellini E, Abenavoli L. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. Rev Recent Clin Trials. 2021; 16 (2): 138–45. DOI: 10.2174/15748871 15666200917110954.PMID: 32940187 Review.
  17. Tleyjeh IM, Kashour Z, Riaz M, Hassett L, Veiga VC, Kashour T. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Clin Microbiol Infect. 2021 Aug; 27 (8): 1076–82. DOI: 10.1016/j.cmi.2021.04.019. Epub 2021 Apr 27.
  18. Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2021 Jan-Feb; 27 (1): 52–66. DOI: 10.1016/j.pulmoe.2020.07.003. Epub 2020 Jul 20. PMID: 32713784.
  19. Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021; 181 (1): 24–31. DOI: 10.1001/ jamainternmed.2020.6615.
  20. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020; 383 (24): 2333–44. DOI: 10.1056/NEJMoa2028836.
  21. Verderese JP, Stepanova M, Lam B, Racila A, Kolacevski A, Allen D, et al. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience. Clin Infect Dis. 2021; DOI: 10.1093/cid/ciab579.
  22. Vremennye metodicheskie rekomendacii # 14 ot 27.12.2021 «Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19)». Russian.
  23. Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS, Siddiqui F. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. J Med Virol. 2020 Nov; 92 (11): 2516–22. DOI: 10.1002/jmv.26038. Epub 2020 Jun 9.